Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma

Primary Objective \- Determine compliance to treatment at 6 and 12 weeks. Compliance is assessed by review of the daily food diary and the urine and serum ketone levels. Diet compliance is defined as following the diet guidelines 80% of the time with resultant ketosis 80% of the time. If 60% of the patients are compliant with the diet, as defined above, that is a considered a positive result. Secondary Objective(s) * Determine patient compliance in monitoring of blood glucose and urine levels of ketosis. * Determine obstacles to compliance. * Determine the frequency of achieving ketosis, as measured by urine ketones checked daily and serum BHB checked every two weeks. * Determine quality of life (FACT-BR) and adverse events. * Determine response, progression free survival at 6 months (PFS 6), and overall survival (OS). Exploratory Objective * To correlate levels of ketosis and blood sugar with treatment outcome. * To correlate the level of MCT4 expression and IDH1 mutation status with treatment outcome.